165 related articles for article (PubMed ID: 21370305)
21. Functional differences of the catalytic and non-catalytic domains in human ADAMTS-4 and ADAMTS-5 in aggrecanolytic activity.
Fushimi K; Troeberg L; Nakamura H; Lim NH; Nagase H
J Biol Chem; 2008 Mar; 283(11):6706-16. PubMed ID: 18156631
[TBL] [Abstract][Full Text] [Related]
22. Specificity of binding with matrix metalloproteinases.
Gupta SP; Patil VM
Exp Suppl; 2012; 103():35-56. PubMed ID: 22642189
[TBL] [Abstract][Full Text] [Related]
23. Analysis of flavonoid-based pharmacophores that inhibit aggrecanases (ADAMTS-4 and ADAMTS-5) and matrix metalloproteinases through the use of topologically constrained peptide substrates.
Cudic M; Burstein GD; Fields GB; Lauer-Fields J
Chem Biol Drug Des; 2009 Nov; 74(5):473-82. PubMed ID: 19793184
[TBL] [Abstract][Full Text] [Related]
24. Cleavage of cartilage oligomeric matrix protein (thrombospondin-5) by matrix metalloproteinases and a disintegrin and metalloproteinase with thrombospondin motifs.
Dickinson SC; Vankemmelbeke MN; Buttle DJ; Rosenberg K; Heinegård D; Hollander AP
Matrix Biol; 2003 May; 22(3):267-78. PubMed ID: 12853037
[TBL] [Abstract][Full Text] [Related]
25. Design and synthesis of a series of (2R)-N(4)-hydroxy-2-(3-hydroxybenzyl)-N(1)- [(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]butanediamide derivatives as potent, selective, and orally bioavailable aggrecanase inhibitors.
Yao W; Wasserman ZR; Chao M; Reddy G; Shi E; Liu RQ; Covington MB; Arner EC; Pratta MA; Tortorella M; Magolda RL; Newton R; Qian M; Ribadeneira MD; Christ D; Wexler RR; Decicco CP
J Med Chem; 2001 Oct; 44(21):3347-50. PubMed ID: 11585439
[TBL] [Abstract][Full Text] [Related]
26. Structure-based design of TACE selective inhibitors: manipulations in the S1'-S3' pocket.
Huang A; Joseph-McCarthy D; Lovering F; Sun L; Wang W; Xu W; Zhu Y; Cui J; Zhang Y; Levin JI
Bioorg Med Chem; 2007 Sep; 15(18):6170-81. PubMed ID: 17606376
[TBL] [Abstract][Full Text] [Related]
27. A dual inhibitor of matrix metalloproteinases and a disintegrin and metalloproteinases, [¹⁸F]FB-ML5, as a molecular probe for non-invasive MMP/ADAM-targeted imaging.
Matusiak N; Castelli R; Tuin AW; Overkleeft HS; Wisastra R; Dekker FJ; Prély LM; Bischoff R; van Waarde A; Dierckx RA; Elsinga PH
Bioorg Med Chem; 2015 Jan; 23(1):192-202. PubMed ID: 25438884
[TBL] [Abstract][Full Text] [Related]
28. Impact of mobility on structure-based drug design for the MMPs.
Moy FJ; Chanda PK; Chen J; Cosmi S; Edris W; Levin JI; Rush TS; Wilhelm J; Powers R
J Am Chem Soc; 2002 Oct; 124(43):12658-9. PubMed ID: 12392402
[TBL] [Abstract][Full Text] [Related]
29. ADAM and ADAMTS Family Proteins and Snake Venom Metalloproteinases: A Structural Overview.
Takeda S
Toxins (Basel); 2016 May; 8(5):. PubMed ID: 27196928
[TBL] [Abstract][Full Text] [Related]
30. Potential role of hyaluronic acid on bone in osteoarthritis: matrix metalloproteinases, aggrecanases, and RANKL expression are partially prevented by hyaluronic acid in interleukin 1-stimulated osteoblasts.
Mladenovic Z; Saurel AS; Berenbaum F; Jacques C
J Rheumatol; 2014 May; 41(5):945-54. PubMed ID: 24737908
[TBL] [Abstract][Full Text] [Related]
31. A Disintegrin and Metalloproteinase (ADAM) and ADAM with thrombospondin motifs (ADAMTS) family in vascular biology and disease.
Zhong S; Khalil RA
Biochem Pharmacol; 2019 Jun; 164():188-204. PubMed ID: 30905657
[TBL] [Abstract][Full Text] [Related]
32. Insights from selective non-phosphinic inhibitors of MMP-12 tailored to fit with an S1' loop canonical conformation.
Devel L; Garcia S; Czarny B; Beau F; LaJeunesse E; Vera L; Georgiadis D; Stura E; Dive V
J Biol Chem; 2010 Nov; 285(46):35900-9. PubMed ID: 20817735
[TBL] [Abstract][Full Text] [Related]
33. Novel N-substituted 2-phenyl-1-sulfonylamino-cyclopropane carboxylates as selective ADAMTS-5 (Aggrecanase-2) inhibitors.
Shiozaki M; Maeda K; Miura T; Ogoshi Y; Haas J; Fryer AM; Laird ER; Littmann NM; Andrews SW; Josey JA; Mimura T; Shinozaki Y; Yoshiuchi H; Inaba T
Bioorg Med Chem Lett; 2009 Mar; 19(6):1575-80. PubMed ID: 19243944
[TBL] [Abstract][Full Text] [Related]
34. Modeling of enzyme-substrate complexes for the metalloproteases MMP-3, ADAM-9 and ADAM-10.
Manzetti S; McCulloch DR; Herington AC; van der Spoel D
J Comput Aided Mol Des; 2003 Sep; 17(9):551-65. PubMed ID: 14713188
[TBL] [Abstract][Full Text] [Related]
35. Altered proteolytic activities of ADAMTS-4 expressed by C-terminal processing.
Kashiwagi M; Enghild JJ; Gendron C; Hughes C; Caterson B; Itoh Y; Nagase H
J Biol Chem; 2004 Mar; 279(11):10109-19. PubMed ID: 14662755
[TBL] [Abstract][Full Text] [Related]
36. Matrix metalloproteinase target family landscape: a chemometrical approach to ligand selectivity based on protein binding site analysis.
Pirard B; Matter H
J Med Chem; 2006 Jan; 49(1):51-69. PubMed ID: 16392792
[TBL] [Abstract][Full Text] [Related]
37. A review of the ADAMTS family, pharmaceutical targets of the future.
Tortorella MD; Malfait F; Barve RA; Shieh HS; Malfait AM
Curr Pharm Des; 2009; 15(20):2359-74. PubMed ID: 19601837
[TBL] [Abstract][Full Text] [Related]
38. The nutraceutical flavonoid luteolin inhibits ADAMTS-4 and ADAMTS-5 aggrecanase activities.
Moncada-Pazos A; Obaya AJ; Viloria CG; López-Otín C; Cal S
J Mol Med (Berl); 2011 Jun; 89(6):611-9. PubMed ID: 21365186
[TBL] [Abstract][Full Text] [Related]
39. Alpha2-macroglobulin is a novel substrate for ADAMTS-4 and ADAMTS-5 and represents an endogenous inhibitor of these enzymes.
Tortorella MD; Arner EC; Hills R; Easton A; Korte-Sarfaty J; Fok K; Wittwer AJ; Liu RQ; Malfait AM
J Biol Chem; 2004 Apr; 279(17):17554-61. PubMed ID: 14715656
[TBL] [Abstract][Full Text] [Related]
40. Crystal structures of MMP-1 and -13 reveal the structural basis for selectivity of collagenase inhibitors.
Lovejoy B; Welch AR; Carr S; Luong C; Broka C; Hendricks RT; Campbell JA; Walker KA; Martin R; Van Wart H; Browner MF
Nat Struct Biol; 1999 Mar; 6(3):217-21. PubMed ID: 10074939
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
